Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/14/2025

Treatment of Small Cell Lung Cancer

Initial Staging and Risk Stratification

  • The National Comprehensive Cancer Network recommends that staging workup should be completed within 1 week to avoid performance status decline in patients with Small Cell Lung Cancer (SCLC) 5
  • Essential staging for SCLC includes CT chest and abdomen with contrast, as recommended by the American Society of Clinical Oncology 1
  • Brain MRI or CT is also essential for identifying asymptomatic CNS metastases in 10-15% of patients at diagnosis, according to the National Comprehensive Cancer Network 5
  • Complete blood count, comprehensive metabolic panel including LDH, liver enzymes, renal function, sodium, and calcium are also necessary for staging, as stated by the American Society of Clinical Oncology 1
  • Bone scan is recommended if clinically indicated, with a positive rate of 30% without bone pain or elevated alkaline phosphatase, as per the National Comprehensive Cancer Network 5

Treatment Algorithm for Limited-Stage Disease

  • The American Society of Clinical Oncology recommends that all patients with limited-stage SCLC and good performance status (ECOG 0-2) should receive concurrent chemoradiotherapy 5
  • Cisplatin plus etoposide for 4-6 cycles is the standard regimen for limited-stage SCLC, with Category 1 evidence, as stated by the National Comprehensive Cancer Network 5
  • Twice-daily radiotherapy (1.5 Gy × 30 fractions) given concurrently with cisplatin-etoposide produces the best overall survival in fit patients, with Level I evidence, according to the American Society of Clinical Oncology 1
  • Prophylactic Cranial Irradiation (PCI) is recommended for all patients with limited-stage disease who achieve response without disease progression and maintain good performance status, with Level I evidence, as per the American Society of Clinical Oncology 1

Treatment Algorithm for Extensive-Stage Disease

  • The American Society of Clinical Oncology recommends that chemotherapy with immunotherapy is the standard first-line treatment for extensive-stage SCLC 2
  • Platinum-etoposide (cisplatin or carboplatin) for 4-6 cycles plus immunotherapy (durvalumab or atezolizumab) followed by maintenance immunotherapy until progression or toxicity is the standard of care, as stated by the National Comprehensive Cancer Network 2
  • Patients with extensive-stage disease who achieve any response to first-line treatment and maintain good performance status should be evaluated for PCI, according to the American Society of Clinical Oncology 1

Second-Line Treatment for Relapsed Disease

  • The National Comprehensive Cancer Network recommends that topotecan (oral or IV) is the FDA-approved standard second-line treatment for relapsed SCLC 2
  • Single-agent topotecan produces response rates of approximately 25% for sensitive relapse (>90 days after first-line therapy), as stated by the National Comprehensive Cancer Network 6
  • Oral topotecan (2.3 mg/m²/day × 5 days) is equally effective as IV administration, according to the National Comprehensive Cancer Network 6

Critical Clinical Considerations and Pitfalls

  • The National Comprehensive Cancer Network recommends avoiding combination chemotherapy in the second-line setting, as it increases toxicity without improving survival compared to single-agent therapy 6
  • Maintenance therapy beyond 4-6 cycles does not substantially improve survival but increases toxicity, as stated by the American Society of Clinical Oncology 3
  • Performance status is crucial, with poor PS patients (3-4) having significantly worse outcomes and may not benefit from aggressive therapy, according to the National Comprehensive Cancer Network 5

Prognostic Factors

  • Adverse prognostic factors for SCLC include poor performance status (3-4), extensive-stage disease, weight loss, and elevated LDH, as stated by the National Comprehensive Cancer Network 5
  • Favorable factors include female gender, age <70 years, normal LDH, and limited-stage disease, according to the National Comprehensive Cancer Network 5